IRVINE, Calif.--(BUSINESS WIRE)--Nov. 12, 2015--
Masimo
(NASDAQ: MASI) announced today that in a new study that compared the end
tidal carbon dioxide values (EtCO2) from both the Masimo EMMA
capnograph and a conventional sidestream capnography device to the
gold-standard carbon dioxide measurement, arterial blood gas (PaCO2),
EMMA produced “reliable” values and had similar accuracy as sidestream
capnography.1
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20151112005734/en/
EMMA resuscitator in use. (Photo: Business Wire)
Carbon dioxide levels in the blood reflect the degree of gas exchange
occurring in the lungs and provide a critical indicator of
cardio-respiratory function that aids in the assessment of the adequacy
of ventilation. PaCO2 is considered the gold standard to
measure carbon dioxide levels but requires invasive blood sampling and
laboratory analysis that can provide intermittent and delayed
measurements. EtCO2 monitoring with capnography provides a
noninvasive and continuous estimate of PaCO2 and has become a
standard of care in the operating room and other critical care areas.2
Since 2010, the American Heart Association (AHA) has recommended the use
of EtCO2 during cardiopulmonary resuscitation (CPR) for
“confirmation and monitoring of endotracheal tube placement.”3
Conventional capnography monitors require warm-up time to calibrate and
measure EtCO2 from a sampling line connected to the breathing
circuit. In contrast to bulkier and slower-to-calibrate sidestream
capnography monitors, the EMMA is a compact and lightweight mainstream
capnograph that clips directly onto the breathing circuit with no
sampling line and minimal warm-up time.
The study, published in the Journal of Clinical Monitoring and
Computing by Dr. Kyung Woo Kim and colleagues from Seoul Park
Hospital, College of Medicine, Seoul, Korea, compared 100 EtCO2
values from both the EMMA and sidestream capnography (Datex Ohmeda S5
Anesthesia Monitor) in 35 patients undergoing general anesthesia to PaCO2
values measured from blood gas analysis (GEM Premier 3000) of
simultaneously collected arterial blood samples. Compared to PaCO2,
EMMA had a bias of 6.0 mm Hg with a percent error of 18% and sidestream
capnography had a bias of 3.8 mm Hg with a percent error of 20%.
The authors concluded “EMMA capnometers are viable and lighter weight
alternatives to legacy capnometers, as they produce capnographs and
reliable EtCO2 values rapidly despite their small size and
light weight.” The authors also noted that “the data used in this study
were only collected in situations of stable and normal respiration under
general anesthesia,” and “that the limitations affecting the prediction
of the PaCO2 values are in accordance with the condition of
the patient.”
For more information on the EMMA capnograph, go to www.masimo.com.
@MasimoInnovates
| #Masimo
-
Kim (et al.), Comparison of end-tidal CO2 measured by transportable
capnometer (EMMA capnograph) and arterial pCO2 in general
anesthesia. J Clin Monit Comput 2015; published online.
-
ASA Standards for Basic Anesthetic Monitoring. 2011.
-
Field (et al.), Part 1: executive summary: 2010 American Heart
Associated ion guidelines for cardiopulmonary resuscitation and
emergency cardiovascular care. Circulation 2010; 122: S640-56.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through-Motion and Low Perfusion™ pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. The benefits of Masimo
SET® have been proven in more than 100 independent and objective studies
and it is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition
to SpO2, pulse rate, and perfusion index (PI). The indications for EMMA
include the following: 1) The EMMA Emergency Capnometer Monitor
measures, displays and monitors carbon dioxide concentration and
respiratory rate during anesthesia, recovery and respiratory care. It
may be used in the operating suite, intensive care unit, patient room,
clinic, emergency medicine and emergency transport settings for adult,
pediatric and infant patients. 2) The EMMA Emergency Capnometer Analyzer
measures and displays carbon dioxide concentration and respiratory rate
during anesthesia, recovery and respiratory care. It may be used in the
operating suite, intensive care unit, patient room, clinic, emergency
medicine and emergency transport settings for adult, pediatric and
infant patients. Additional information about Masimo and its products
may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151112005734/en/
Source: Masimo
Masimo
Media Contact:
Irene Paigah, 858-859-7001
irenep@masimo.com